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Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour
which arises from thyroid C-cells. It accounts for 5 to 10% of all
thyroid cancers. Total thyroidectomy with lymph node dissection
is the main treatment when the disease is confined to the neck (Chi
and Moley, 1998; Schlumberger and Pacini, 1999). External irradi-
ation to the neck may be indicated in the absence of known distant
disease, in patients with a detectable CT level after an apparently
complete surgical procedure, and in those with an inoperable
disease (Tubiana et al, 1985; Brierley et al, 1996; Fife et al, 1996).
This procedure reduces the recurrence rate in the neck, but its
impact on patients’ survival has still to be demonstrated.
Chemotherapy plays no role in the early management (Chi and
Moley, 1998; Schlumberger and Pacini, 1999).
This disease usually follows an indolent course even at the stage
of distant spread, and patients with lung or liver metastases may
survive years without systemic treatment (Saad et al, 1984;
Tubiana et al, 1985; Van Heerden et al, 1990; Chi and Moley,
1998; Brierley et al, 1996). In a minority of these metastatic
patients, chemotherapy may be indicated for rapidly progressive
distant metastases (Cailleux and Schlumberger, 1998).
Chemotherapy trials have been limited by the scarcity of these
tumours. Furthermore, due to the indolent course of the disease
and the poor results of chemotherapy, only patients with large
tumour burden or rapidly progressing distant metastases have been
included in these trials. Response rates were low with doxorubicin
(Shimaoka et al, 1985; Droz et al, 1990) and cisplatin (Hoskin and
Harmer 1987; Droz et al, 1990), given either as single agents or in
combination (Shimaoka et al, 1985; Williams et al, 1986; De Besi
et al, 1991). Furthermore, toxicities were significant.
A trial (Schlumberger et al, 1995) with etoposide given as a
single agent did not confirm a previous report (Hoskin and
Harmer, 1987) as no tumour response was observed among 16
evaluable patients.
Combination of drugs which have been shown to be active in
the treatment of other neuroendocrine tumours may provide
further therapeutic options in MTC patients. Indeed, several trials
carried out on limited numbers of MTC patients have shown that
these drugs are active in some. With the combination of 5FU-
dacarbazine, a complete response was observed in one patient
(Pertusson, 1988), and 3 partial responses were observed among 5
patients (Orlandi et al, 1994). Two partial responses were observed
among 7 patients treated with cyclophosphamide, vincristine and
dacarbazine (Wu et al, 1994). With a combination of doxorubicin
and streptozocin, one partial response was obtained among 5
patients (Frame et al, 1988), and using a combination of epiru-
bicin, 5-FU and dacarbazine, one partial response was observed
among 7 patients (Di Bartolomeo et al, 1995). In a previous study
(Schlumberger et al, 1995), combinations of 5-FU/streptozocin
and 5-FU/dacarbazine were given alternatively to 20 patients.
Three partial responses and 11 stabilizations were observed.
Considering these results, the alternating combinations of
doxorubicin/streptozocin and 5-FU/dacarbazine, that have already
been used in gastro-entero-pancreatic neuroendocrine tumours
(Moertel et al, 1994), were given to 20 patients with progressive
metastatic MTC.
PATIENTS AND METHODS
Patients
From October 1994 to February 1999, 20 patients (Table 1) with
progressive distant metastases of MTC were entered into this trial.
Their mean age was 49 years (range 30–79). There were 14 males
and 6 females. Among them, 16 had undergone a total thyroidec-
tomy with bilateral cervical lymph node dissection, and 10 had
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mediastinum. Four patients were not operated on for diffuse
distant metastases at presentation or locally advanced disease.
None of them had previously been treated with chemotherapy.
Median follow-up since the diagnosis was 4.5 years (range, 2.3–37
years).
All patients had measurable metastatic lesions that were docu-
mented by chest radiography, neck or liver ultrasonography, and
neck, chest or abdominal CT scan or magnetic resonance imaging.
These lesions have progressed during the preceding 3–6 months.
The tumour markers calcitonin (CT) and carcinoembryonic
antigen (CEA) were measured and followed in all patients but
were not accepted as the only response criteria.
Other eligibility requirements were as follows: ECOG status <2,
no major ECG changes and an ejection fraction >50% as measured
by an isotopic technique; leucocyte count greater than 4000 µ l–1
and platelet count greater than 150 000 µ l–1, a serum creatinine of
120 µ mol l–1 or less, a 24 h proteinuria <200 mg, a total bilirubin
of less than or equal to 34 µ mol l–1.
All patients were evaluated upon entry into the study, and after
every 2 courses of chemotherapy, with clinical staging, CT and
CEA measurements and morphological investigations including
chest X-ray, neck and liver ultrasonography and chest or abdom-
inal CT scan. Routine chemistry and ECG were performed before
each course of chemotherapy.
The study was approved by the local Ethics Committee and an
informed consent was obtained from all patients.
Treatment
The chemotherapy protocol consisted in doxorubicin 60 mg/m2 i.v.
in 5 minutes on day 1, and streptozocin 500  mg/m2 in 4 hours
perfusion, daily for 5 consecutive days. Four weeks later, 5-FU
was given at 400 mg/m2, and dacarbazine at 200 mg/m2, both by
intravenous injection daily for 5 consecutive days. At 8 weeks, this
cycle was repeated.
Three categories of response were assessed: (1) tumour, (2)
biochemical, and (3) symptomatic. The criteria used for reporting
responses for measurable tumour masses were those of Miller et al
(1981): partial remission (PR) was defined as greater than or equal
to 50% decrease in the sum of the products of the two largest
perpendicular diameters of all tumour masses for at least 1 month;
no change (NC), defined as less than 50% decrease or less than
25% increase in the size of measurable lesions; progressive
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Table 1 Clinical characteristics of the twenty patients included in the trial
Patient Sex/Age Type Metastatic sites Surg RT PS No of Tumour Marker response Toxicity Response Survival after 
(years) courses response CT CEA (WHO grade) duration chemotherapy
(months) (months)
1 M/52 S Lungs, bones, liver + – 0 6 PR PR NC Vomiting (2) 27 33D
2 F/63 S Nodes, trachea + – 0 4 NC PR P Vomiting (3) 16 31D
3 M/45 S Lungs, bones, liver + + 0 6 PR PR PR Cardio (3) 18 39A
nodes
4 M/46 S Lungs, bones + + 2 3 P NC NC Diarrhea(3) – 12D
nodes
5 M/58 S Liver + + 0 6 NC NC NC Cardio (3) 18 24D
6 M/69 S Lungs, bones + – 0 6 NC NC PR Leucopenia (4) 13+ 13A
nodes
7 M/69 S Lungs, bones, liver + – 3 2 P P P – – 12A
8 M/38 F Lungs, liver + – 0 4 NC NC NC – 8+ 8A
9 M/30 S Lungs, bones + – 0 6 NC NC NC Liver(2) 12+ 12A
10 M/43 S Lungs, bones, liver – – 1 2 P P NC – – 19D
nodes, spleen
11 M/50 S Trachea + + 0 4 PR PR – – 28+ 28A
12 F/42 F Bones, liver + + 0 6 NC P P Stomatitis (2) 48 60A
Lungs, nodes
13 F/47 S Bones, liver + + 0 6 NC P NC – 14 19A
Lungs, nodes
14 F/79 S Bones, liver + + 1 2 P P P – – 8D
15 M/40 S Bones, liver + – 0 6 NC P NC Alopecia (4) 51+ 51A
Lungs, nodes
16 F/39 S Lungs, liver + + 0 4 NC PR PR Vomiting (2) 25 39A
17 F/34 S Lungs, nodes + + 0 5 NC PR P Alopecia (3) 25 34A
Pleura
18 M/60 S Lungs, nodes – + 0 4 P P P Leucopenia (3) – 18D
19 M/32 S Lungs, liver – – 1 2 P P P Vomiting (2) – 24A
20 M/51 S Bones, liver – – 0 3 P P P – – 26A
Lungs, nodes
M: males; F: females; S: sporadic; F: familial; RT: cervico-mediastinal irradiation; PS: performance status; CT: calcitonin; CEA: carcinoembryonic antigen; PR:
partial response; NC: no change; P: progression; D: death; A: alivedisease (P) defined as greater than or equal to 25% increase in any
tumour lesion or the appearance of new site. For biochemical
response, PR was defined as greater than or equal to 50% decrease
for at least 1 month. For symptomatic response, PR was defined as
a reduction of at least 50% in both the frequency and intensity of
flushing and/or diarrhoea attacks. In those patients who achieved a
partial response, the period of overall duration of response was
calculated from the first day of treatment to the date of first obser-
vation of progressive disease.
Toxicity was evaluated monthly and complete re-staging was
performed after 2, 4 and 6 cycles of chemotherapy. Therapy was
continued until tumour progression, and in cases of tumour
response or stabilization for a total of 6 cycles (12 months), and as
long as there was no evidence of symptomatic or general deterio-
ration or toxicity.
RESULTS
The 20 patients entered into this trial were evaluable for toxicity
and response. Each patient received an average of 4 (range 2 to 6)
cycles of doxorubicin-streptozocin and 5-FU-dacarbazine.
Four of the 5 patients with invalidating symptoms before
starting chemotherapy had a partial symptomatic response.
Three partial tumour responses were obtained after 3, 2 and 3
cycles of chemotherapy, and lasted 27, 28+ and 18 months, respec-
tively. Calcitonin level decreased by 65%, 73% and 58% respec-
tively, and CEA level was stable in one patient, was normal in one
before therapy, and decreased by 60% in one.
Ten patients had a stable disease for 8–51 months (mean 23
months). Among these 10 patients, 3 had progressive marker
levels, 4 had stable marker levels and 3 had a partial biological
response. Seven patients had progressive disease.
Nausea and vomiting were limited by antiemetic drugs and
digestive toxicity was observed in 5 patients (grade 2 in 3 and
grade 3 in 2). One patient had a grade 2 stomatitis. Hepatic toxicity
(grade 2) was observed in one patient, haematologic toxicity in 2
patients (grade 3 and 4), and cardiac toxicity in two patients (grade
3). There were no treatment-related deaths.
With a mean follow-up of 25 months (range, 8–60 months)
since the beginning of therapy, seven deaths occurred, including
one among the 3 patients who had responded to therapy, 2 among
the 10 patients who achieved a stabilisation of the disease, and 4 in
the 7 patients with progressive disease.
DISCUSSION
The alternating combination of doxorubicin-streptozocin, and 5-
FU-dacarbazine, was used because it combines drugs that have
been shown to be active in medullary thyroid carcinoma, when
used separately; also, this association has been shown to be active
in other neuroendocrine tumours, with an acceptable toxicity
(Moertel et al, 1994).
In 20 patients with metastatic MTC, it resulted in 3 partial
responses (15%), and in 10 long-term stabilisations (50%).
Considering that all patients included in the trial were affected by a
rapidly progressing disease, these results confirm the potential
benefits of cytotoxic chemotherapy, and are in agreement with the
results obtained with the association of epirubicin, dacarbazine
and 5-FU (Di Bartolomeo et al, 1995).
Nevertheless, the response rate was not improved by adding
doxorubicin to the previously tested regimen of streptozocin plus
5-FU and dacarbazine, and toxicity was slightly higher
(Schlumberger et al, 1995). Therefore, we consider the previous
regimen as the reference combination for metastatic MTC patients
with rapidly progressing disease. The absence of synergistic effect
among these cytotoxic agents can be attributed to the large size of
the neoplastic masses and also to intrinsic cellular factors deter-
mining chemoresistance (Yang et al, 1991).
Nevertheless, because of the high metastatic potential of
medullary thyroid carcinoma, further studies are necessary in
order to identify new therapeutic strategies with cytotoxic or cyto-
static molecules that will permit the treatment of these patients at
an earlier stage.
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